Effects of fish oil supplementation on inflammatory markers in chronic heart failure: a meta-analysis of randomized controlled trials

Table 1 Overview and characteristics of included studies

Study	No.of patients	Mean age	Male	Ischemic etiology	Mean NYHA	Mean LVEF	ACEI/ARB	β-blocker	Statins	EPA + DHA dose	EPA dose	DHA dose	EPA/DHA	Duration	Placebo	Study design	Quality score
		y	%	%		%	%	%	%	mg/d	mg/d	mg/d		months
Mehra 2006	14	60	71	43	III-IV	17	93	64	0	5440	3520	1920	1.83	4	Corn oil	R, DB, PC	3
O'Keefe 2006	18	68	100	100	NR	NR	NR	78	83	810	225	585	0.38	4	Corn oil & olive oil	R, DB, PC, CO	3
Nodari 2009	44	63	91	0	II-III	36.2	100	100	NR	1440	540	900	0.60	6	Olive oil	R, DB, PC	3
Zhao 2009	75	73	73	64	II-III	31	100	87	NR	600	360	240	1.50	3	NR	R, SB, PC	3
Eschen 2010	138	60	86	68	II-III	32	95	88	54	900	490	410	1.20	6	Olive oil	R, DB, PC	3
Moertl 2011 a	22	57	83	0	III-IV	24.3	100	100	NR	840	465	375	1.24	3	Gelatin	R, DB, PC	5
Moertl 2011 b	21	60	94	0	III-IV	24.2	100	100	NR	3360	1860	1500	1.24	3	Gelatin	R, DB, PC	5
Nodari 2011	133	63	75	0	I-II	36.5	100	100	14	1950	730	1220	0.60	12	Olive oil	R, DB, PC	3

The study by Moertl et al. includes two intervention groups of different dosages of EPA + DHA (Moertl 2011a, EPA + DHA 840 mg/day and Moertl 2011b, EPA + DHA 3360 mg/day).
NYHA, New York Heart Association; LVEF, left ventricular ejection fraction; ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; EPA, eicosapentaenoic acid; DHA, ducosahexenoic acid; R, random; DB, double blind; SB, single blind; PC, placebo-controlled; CO, crossover; NR, not reported.

ISSN: 1471-2261